HatchMed wins marketing for ELUNATE® (fruquintinib)
— First drug approved under Hong Kong Special Administrative Region Government’s new ‘1+’ mechanism provides important treatment option for Hong Kong patients — — Erunate® This is the first oral targeted therapy approved for metastatic colorectal cancer in Hong Kong in nearly a decade, regardless of biomarker status or previous treatment. — Fruquintinib is already […]